Results 81 to 90 of about 3,536 (218)
European Journal of Haematology, EarlyView.ABSTRACT Background Acute kidney injury (AKI) is a frequent and clinically relevant complication in allogeneic hematopoietic cell transplantation (HCT) recipients, particularly during the early post‐HCT period. Although AKI has been extensively reported in long‐term follow‐up studies, data focusing on the initial hospitalization phase remain limited ...
Luiz Carlos da Costa‐Junior +10 more
wiley +1 more source
Bringing Gene Therapy Into Real World Clinical Practice
Haemophilia, EarlyView.ABSTRACT Introduction Adeno‐associated virus (AAV)‐based gene therapy for haemophilia has shifted therapeutic paradigms by enabling hepatic gene transfer, restoring endogenous clotting factor expression, and reducing reliance on conventional prophylactic treatments. Two products, valoctocogene roxaparvovec (haemophilia A) and etranacogene dezaparvovec (
Wolfgang Miesbach +2 more
wiley +1 more source
Cancer-related thrombotic microangiopathies: case report and narrative review
Italian Journal of Medicine, 2018 Thrombotic manifestations are common in cancer patients and increase morbidity and mortality. They can affect large or small, venous or arterial vessels. Thrombosis of large arteries and veins is much more studied than that of small vessels. Nevertheless,
Micaela La Regina +5 more
doaj +1 more source
FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives
Haemophilia, EarlyView.ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita +2 more
wiley +1 more source
The Complement System in Post‐Transplant Kidney Injury
Organ Medicine, EarlyView.
Mengsi Hu
wiley +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima +8 more
wiley +1 more source
Cardiac involvement in thrombotic microangiopathies
Терапевтический архив, 2015 Aim. To describe cardiac involvement in patients with acute thrombotic microangiopathy (TMA). Materials and methods. The case histories of 46 patients with proven TMA, including 17 patients diagnosed with atypical hemolytic uremic syndrome (aHUS) and 29 ...
D S Tuter +6 more
doaj
How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome
, 2014 Thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic uraemic syndrome (aHUS) are acute, rare life-threatening thrombotic microangiopathies that require rapid diagnosis and treatment.
Goodship, T, Scully, M
core
Tacrolimus-induced, Transplant-associated Thrombotic Microangiopathies after Lung Transplantation [PDF]
, 2017 We report a case of tacrolimus-induced transplant-associated thrombotic microangiopathies (TA-TMA) after lung transplantation. A 71-year-old man underwent lung transplantation secondary to idiopathic pulmonary fibrosis.
백효채 +8 more
core +1 more source
Haemophilia, EarlyView.ABSTRACT Introduction Prophylactic factor replacement and non‐factor therapy has improved bleed prevention and clinical outcomes for people with haemophilia (PwH). The remaining burdens faced by PwH in real‐world settings, despite availability of newer therapies, are not well documented.
Víctor Jiménez Yuste +5 more
wiley +1 more source